BUZZ - Oracle shares decline, Blue Owl shares tumble after reports the company issued a force majeure notice.
路透社2026/09/24 13:11September 24 - ** In pre-market trading on Thursday, Oracle ORCL.N shares fell 4.3% to $138.50, after Bloomberg reported (link) that the company is seeking exemption for a certain data center project on the grounds of "force majeure."
** According to Bloomberg, citing sources familiar with the matter, Oracle sent notice to a project developer in New Mexico to guard against potential risk of rising costs.
** Blue Owl OWL.N shares fell 5.2%.
** According to Markit data, Oracle's (ORCL) 5-year credit default swap ORCL5YUSAX=MG reached a record high of 221.78 basis points.
** Reuters could not independently verify the report.
** ORCL has plunged approximately 25.8% so far this year, underperforming the S&P 500 Index .SPX which is up 12.6%. The current share price is about 55% lower than its 52-week intraday high of $322.54.
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. However, because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it merely for the convenience of readers. Reuters bears no responsibility for any damages or losses resulting from use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
